Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReFacto AF versus Advate bioequivalence and safety study in previously treated hemophilia A
2005-000720-16Phase 3Completed
- Sponsor
- Wyeth
- Start
- May 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of recombinant human coagulation factor VIII in hemophilia A (3 arms), sponsored by Wyeth. Primary endpoints: Factor VIII inhibitor incidence and Safety and efficacy of ReFacto AF in prevention and treatment of bleeding. Started May 2005; status: completed.
02
Drugs
recombinant human coagulation factor VIII
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2005-000720-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000720-16.